Decision: Favourable
Study Title:
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
NREC Code:
22-NREC-CT-103
Decision:
Favourable
Meeting Date:
08/06/2022
Study Type:
CT application
Principal Investigator:
Prof Emer Joyce
PI Institution:
Mater Misericordiae University Hospital
Sponsor:
Eidos Therapeutics, Inc.